Home > Insider Trading > Filing (0001209191-13-031639)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1333248	Cadence Pharmaceuticals Inc	CADX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1466916	A. Scott Byrd	C/O Cadence Pharmaceuticals, Inc. 12481 High Bluff Drive, Ste 200 San Diego CA 92130	Svp, Chief Commercial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2013-06-07	30,657	$3.51	32,657	No	4	M	Direct
Common Stock	Acquisiton	2013-06-07	36,458	$3.51	69,115	No	4	M	Direct
Common Stock	Disposition	2013-06-07	67,115	$7.53	2,000	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	stock option (right to buy)	Disposition	2013-06-07	30,657	$0.00	30,657	$3.51
Common Stock	stock option (right to buy)	Disposition	2013-06-07	36,458	$0.00	36,458	$3.51

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2012-09-14	2022-03-14	No	4	M	Direct
88,542		2022-03-14	No	4	M	Direct

Footnotes

The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 7, 2013.
This transaction was executed in multiple trades at prices ranging from a low of $7.39 to a high of $7.79. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Not applicable to this transaction.
31,250 of the options vested and became exercisable on March 14, 2013; and 2,604 of the options vested and became exercisable on each of April 1, 2013 and May 1, 2013.